Inventiva S.A. (IVA) |
|
5.175 0.305 (6.26%)
|
08-19 01:46 |
|
Open: |
5.175 |
Pre. Close: |
4.87 |
|
High:
|
5.175 |
Low:
|
4.88 |
|
Volume:
|
230 |
Market Cap:
|
215(M) |
|
|
|
|
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.04 - 5.06 |
5.06 - 5.09 |
|
Low:
|
4.8 - 4.84 |
4.84 - 4.87 |
|
Close:
|
4.96 - 5.01 |
5.01 - 5.05 |
|
Technical analysis |
as of: 2022-08-18 3:53:48 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 6.52 One year: 7.62 |
| Support: |
Support1: 4.78 Support2: 4.28 |
| Resistance: |
Resistance1: 5.59 Resistance2: 6.52 |
| Pivot: |
4.84 |
| Moving Average: |
MA(5): 5.18 MA(20): 4.89
MA(100): 7.74  MA(250): 10.99 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 62.2 %D(3): 67.9 |
| RSI: |
RSI(14): 49.4 |
| 52-week: |
High: 15.77 Low: 4.28 |
| Average Vol(K): |
3-Month: 29 (K) 10-Days: 2 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IVA ] has closed below upper band by 22.7%. Bollinger Bands are 31.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 18 Aug 2022
Weddle, Iva Leo - NRVN News
Thu, 18 Aug 2022
The Global Intelligent Virtual Assistant (IVA) Based Banking Market size is expected to reach $5.1 billion by 2028, rising at a market growth of 24.3% CAGR during the forecast period - GlobeNewswire
Thu, 18 Aug 2022
Iva L. Seefeldt | News, Sports, Jobs - Fairmont Sentinel
Wed, 17 Aug 2022
What Kind Of Investors Own Most Of Inventiva S.A. (EPA:IVA)? - Simply Wall St
Sun, 14 Aug 2022
Iva Whitson Obituary (1938 - 2022) - Vinton, VA - Legacy.com
Sat, 13 Aug 2022
Iva Lea Carter | Local | rapidcityjournal.com - Rapid City Journal
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
41 (M) |
| Shares Float |
14 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
11.9 (%) |
|
Shares Short
|
136 (K) |
|
Shares Short P.Month
|
128 (K) |
Stock Financials |
|
EPS
|
-1.34 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.17 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-613.2 |
|
Return on Assets (ttm)
|
-25 |
|
Return on Equity (ttm)
|
-49.7 |
|
Qtrly Rev. Growth
|
81.8 |
|
Gross Profit (p.s.)
|
0.18 |
|
Sales Per Share
|
0.2 |
|
EBITDA (p.s.)
|
-1.26 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-48 (M) |
|
Levered Free Cash Flow
|
-24 (M) |
Stock Valuations |
|
PE Ratio
|
-3.89 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.38 |
|
Price to Sales
|
24.88 |
|
Price to Cash Flow
|
-4.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
